lassa
fever
acut
viral
hemorrhag
ill
viru
endem
west
africa
also
concern
regard
bioterror
transmiss
lassa
viru
human
may
occur
direct
contact
infect
blood
bodili
secret
oral
administr
antivir
drug
ribavirin
often
consid
postexposur
prophylaxi
systemat
collect
data
uniform
guidelin
exist
indic
furthermor
rel
low
secondari
attack
rate
lassa
fever
restrict
area
endem
west
africa
infrequ
highrisk
exposur
make
unlik
control
prospect
efficaci
trial
ever
possibl
recommend
postexposur
use
ribavirin
therefor
made
basi
thorough
understand
logic
extrapol
exist
data
review
pertin
issu
propos
guidelin
base
extens
review
literatur
well
experi
field
recommend
oral
ribavirin
postexposur
prophylaxi
lassa
fever
exclus
definit
highrisk
exposur
guidelin
may
also
serv
exposur
hemorrhag
fever
virus
suscept
ribavirin
nosocomi
transmiss
outbreak
describ
health
care
facil
area
endem
laboratori
diagnosi
lassa
fever
achiev
variou
method
includ
enzymelink
immunosorb
assay
polymeras
chain
reaction
pcr
viru
cultur
reagent
assay
wide
avail
detect
infect
incub
period
ribavirin
guanosin
analogu
broadspectrum
virustat
activ
drug
use
vari
degre
proven
clinic
efficaci
treatment
lassa
fever
arenaviru
infect
junin
machupo
virus
hemorrhag
fever
renal
syndrom
crimeancongo
hemorrhag
fever
hepat
c
respiratori
syncyti
viru
pneumonia
la
cross
enceph
influenza
adenoviru
infect
variou
mechan
action
ribavirin
suggest
includ
direct
inhibit
viral
rnadepend
rna
polymeras
inhibit
host
inosin
monophosph
dehydrogenas
modul
host
immun
respons
inhibit
viral
cap
advers
effect
associ
oral
ribavirin
occur
prolong
use
week
month
although
mild
decreas
red
blood
cell
count
report
day
administr
especi
children
enzym
lethal
mutagenesi
specif
mechan
action
ribavirin
lassa
viru
investig
administr
intraven
ribavirin
within
first
day
ill
shown
decreas
mortal
sever
lassa
fever
oral
ribavirin
also
efficaci
less
intraven
form
ribavirin
associ
number
advers
effect
although
mild
revers
cessat
dose
reduct
drug
tabl
although
death
use
oral
ribavirin
known
occur
chest
pain
thought
due
coronari
ischemia
exacerb
anemia
report
ribavirin
teratogen
embryotox
rodent
therefor
contraind
pregnanc
breastfeed
although
high
matern
fetal
mortal
associ
lassa
fever
pregnanc
may
outweigh
risk
demonstr
efficaci
intraven
ribavirin
lassa
fever
communic
natur
lassa
viru
inabl
diagnos
lassa
fever
incub
period
frequent
prompt
consider
oral
ribavirin
postexposur
prophylaxi
pep
often
set
consider
anxieti
health
care
worker
famili
member
expos
person
subsequ
receiv
diagnosi
lassa
fever
howev
systemat
collect
data
uniform
guidelin
use
dose
durat
therapi
exist
ribavirin
indic
caus
consider
confus
furthermor
rel
low
secondari
attack
rate
lassa
fever
restrict
area
endem
west
africa
infrequ
import
case
highrisk
exposur
contact
discuss
mode
transmiss
attack
rate
literatur
review
pertin
issu
section
make
unlik
control
prospect
efficaci
trial
ribavirin
pep
lassa
fever
ever
possibl
absenc
efficaci
data
recommend
use
ribavirin
indic
made
basi
thorough
understand
logic
extrapol
exist
data
review
pertin
issu
propos
guidelin
use
ribavirin
pep
lassa
fever
base
extens
review
literatur
well
consider
experi
field
decis
use
pep
given
exposur
logic
base
riskbenefit
analysi
take
account
aspect
diseas
mode
transmiss
attack
rate
incub
period
pathogenesi
mortal
drug
efficaci
advers
effect
eas
administr
cost
patient
willing
anxieti
regard
pep
premorbid
condit
concomit
medic
key
element
aspect
review
although
mani
remain
poorli
character
use
ribavirin
pep
lassa
fever
although
aerosol
transmiss
postul
clinic
epidemiolog
observ
past
year
provid
convinc
evid
direct
exposur
blood
bodili
secret
usual
requir
transmiss
lassa
viru
human
secondari
attack
rate
lassa
fever
nosocomi
set
appear
quit
low
long
adequ
barrier
nurs
maintain
norm
industri
countri
among
import
case
least
cumul
identifi
contact
report
sinc
singl
put
asymptomat
instanc
secondari
transmiss
lassa
viru
note
sanzon
person
commun
incub
period
pathogenesi
incub
period
lassa
fever
usual
day
rang
day
onset
typic
insidi
difficult
diagnos
clinic
mean
alon
macrophag
dendrit
cell
initi
target
infect
follow
hematogen
seed
wide
varieti
cell
organ
along
product
host
inflammatori
vasoact
mediat
play
major
role
diseas
mortal
contrari
public
percept
overal
mortal
lassa
fever
appear
low
howev
mortal
data
deriv
primarili
infect
josiah
strain
close
variant
circul
sierra
leon
liberia
guinea
strain
nigeria
often
consid
virul
sever
fatal
diseas
may
occur
strain
lassa
viru
third
trimest
pregnanc
matern
fetal
mortal
elev
prognost
indic
known
would
identifi
prior
diseas
onset
patient
ultim
develop
sever
lassa
fever
pep
would
logic
indic
anecdot
morbid
mortal
seem
increas
expatri
rel
nativ
african
dgb
unpublish
observ
whether
repres
genet
differ
suscept
consequ
partial
immun
previou
infect
popul
indigen
area
endem
unknown
efficaci
although
drug
frequent
given
potenti
exposur
lassa
viru
data
exist
efficaci
ribavirin
pep
lassa
fever
human
anecdot
observ
difficult
interpret
low
attack
rate
none
contact
prescrib
oral
ribavirin
pep
mgkg
time
day
day
consid
highrisk
exposur
import
case
lassa
fever
germani
becam
sick
although
lassa
virusspecif
immunoglobulin
g
igg
igm
antibodi
detect
one
person
start
ribavirin
h
exposur
person
never
travel
area
lassa
fever
endem
preexposur
serum
sampl
avail
determin
whether
seroconvers
occur
adher
prescrib
regimen
advers
effect
report
studi
ribavirin
pep
anim
model
lassa
fever
show
efficaci
intraven
intramuscular
rout
administr
test
ribavirin
given
intraven
mgkg
load
dose
follow
mgkg
everi
h
intramuscularli
mgkg
load
dose
follow
mgkg
time
day
shown
protect
nonhuman
primat
fatal
lassa
fever
start
day
infect
protect
enhanc
ribavirin
given
combin
immun
serum
intraven
ribavirin
pep
intramuscular
ribavirin
pep
also
shown
efficaci
nonhuman
primat
model
junin
viru
infect
given
day
infect
howev
intraven
intramuscular
rout
use
studi
produc
serum
level
ribavirin
significantli
achiev
oral
administr
usual
use
pep
extens
pharmacolog
test
ribavirin
lassa
fever
perform
cell
cultur
experi
ribavirin
report
minimum
inhibitori
concentr
ribavirin
concentr
rang
mic
ic
lassa
viru
achiev
rel
easili
intraven
administr
singl
dose
mg
produc
peak
serum
concentr
mmol
l
ribavirin
patient
lassa
fever
produc
mean
peak
serum
level
mmoll
day
mg
administ
intraven
daili
mg
everi
h
mmoll
continu
treatment
mg
administ
intraven
everi
h
day
singl
studi
drug
efficaci
treatment
lassa
fever
human
assess
dose
intraven
ribavirin
use
load
dose
follow
g
everi
h
day
follow
mg
everi
h
day
total
cours
day
reach
target
mic
ic
oral
ribavirin
less
certain
steadyst
level
oral
ribavirin
occur
week
administr
despit
rapid
extens
absorpt
proxim
small
bowel
firstpass
hepat
metabol
result
oral
bioavail
peak
plasma
level
typic
order
magnitud
less
seen
intraven
administr
oral
administr
singl
dose
mg
produc
peak
plasma
level
mmoll
patient
lassa
fever
take
oral
ribavirin
mgday
divid
dose
day
mean
peak
plasma
concentr
mmoll
rang
mmoll
borderlin
serum
level
probabl
explain
decreas
efficaci
oral
ribavirin
compar
intraven
ribavirin
treatment
lassa
fever
advers
effect
eas
administr
advers
effect
either
biolog
anxieti
induc
frequent
oral
ribavirin
pep
often
lead
decreas
adher
exampl
host
minor
advers
effect
note
person
given
oral
ribavirin
pep
mg
time
day
day
possibl
exposur
import
case
lassa
fever
london
prompt
person
stop
take
drug
anoth
person
decreas
dose
similar
problem
report
use
ribavirin
pep
follow
import
case
lassa
fever
south
africa
l
blumberg
person
commun
despit
frequenc
minor
advers
effect
risk
shortterm
administr
day
requir
pep
lassa
fever
appear
minim
although
special
consider
may
requir
regard
ribavirin
use
popul
comorbid
condit
especi
anemia
human
immunodefici
viru
hiv
infect
renal
insuffici
common
west
africa
lassa
fever
endem
cost
ribavirin
capsul
tablet
avail
va
rieti
pharmaceut
compani
primarili
unit
state
china
switzerland
cost
dose
rang
cent
tabl
pep
sort
obvious
indic
patient
predispos
adher
regimen
concomit
medic
premorbid
condit
especi
might
limit
gut
absorpt
exacerb
anemia
would
major
consider
withhold
pep
although
safeti
cost
profil
ribavirin
pep
lassa
fever
favor
believ
overal
data
argu
liber
use
drug
indic
follow
reason
secondari
attack
rate
lassa
fever
circumst
low
efficaci
ribavirin
pep
unknown
reach
mic
ic
lassa
viru
assur
oral
administr
toler
dose
advers
event
frequent
may
pose
challeng
patient
doctor
distinguish
earli
symptom
lassa
fever
typic
insidi
onset
liber
use
ribavirin
pep
might
unintent
encourag
clinician
caretak
let
guard
regard
infect
control
practic
believ
infect
necessarili
seriou
event
avail
pep
recommend
ribavirin
pep
lassa
fever
exclus
event
definit
highrisk
exposur
defin
follow
penetr
skin
contamin
sharp
instrument
eg
needlestick
injuri
contamin
mucou
membran
broken
skin
blood
bodili
secret
eg
blood
splash
eye
mouth
particip
emerg
procedur
eg
resuscit
cardiac
arrest
intub
suction
without
use
appropri
person
protect
equip
prolong
ie
hour
continu
contact
enclos
space
without
use
appropri
person
protect
equip
eg
health
care
worker
accompani
patient
medic
evacu
calcul
risk
infect
clinician
realiz
titer
lassa
viru
blood
bodili
secret
correl
diseas
sever
infecti
patient
sever
clinic
condit
usual
late
cours
ill
case
exposur
index
case
must
period
acut
febril
ill
evid
lassa
viru
transmiss
incub
period
recoveri
except
sexual
transmiss
transmiss
rare
occur
delay
clearanc
month
acut
infect
lassa
viru
gonad
instanc
ribavirin
pep
indic
propos
oral
regimen
load
dose
maximum
dose
g
follow
mgkg
maximum
dose
g
time
day
day
adult
translat
load
dose
follow
g
taken
time
day
regimen
deriv
standard
intraven
dose
take
account
mean
oral
bioavail
theoret
requir
doubl
intraven
dose
given
oral
modif
toler
eas
administr
repres
cumul
mainten
dose
compar
standard
intraven
regimen
may
achiev
target
mic
lassa
viru
case
howev
consid
mortal
lassa
fever
correl
viral
load
prophylaxi
therapi
lower
level
viremia
could
reason
presum
decreas
sever
even
diseas
still
occur
ribavirin
excret
primarili
kidney
therefor
dose
decreas
person
known
signific
renal
insufficieci
creatinin
clearanc
mlmin
although
use
intraven
ribavirin
pep
would
skirt
shortcom
oral
form
includ
reliabl
achiev
mic
lassa
viru
avoid
gastric
toxic
approach
come
drawback
includ
morecumbersom
administr
increas
hematotox
significantli
increas
cost
mean
wholesal
price
unit
state
cours
intraven
ribavirin
gener
form
avail
given
disadvantag
consid
low
secondari
attack
rate
recommend
intraven
ribavirin
pep
lassa
fever
oral
ribavirin
start
immedi
highrisk
exposur
counsel
patient
physician
drug
taken
food
patient
inform
efficaci
pep
lassa
fever
unknown
although
major
risk
use
minor
advers
effect
often
occur
alreadi
perform
index
case
test
lassa
fever
cessat
ribavirin
test
result
neg
patient
receiv
oral
ribavirin
pep
develop
manifest
lassa
fever
also
immedi
laboratori
test
lassa
fever
sensit
method
usual
reversetranscriptas
pcr
treatment
switch
intraven
form
unless
diseas
readili
exclud
physician
awar
possibl
ribavirin
pep
might
prolong
incub
period
lassa
fever
might
complet
prevent
diseas
although
specif
document
ribavirin
pep
lassa
fever
viral
ill
emerg
ribavirinresist
lassa
viru
report
although
oral
regimen
similar
recommend
use
treatment
crimeancongo
hemorrhag
fever
viru
report
side
effect
mild
anemia
thrombocytosi
frequent
gener
mild
advers
effect
expect
particular
attent
anemia
asymptomat
jaundic
may
develop
patient
gilbert
syndrom
signific
variabl
toler
ribavirin
may
note
especi
patient
hiv
infect
renal
insuffici
comorbid
condit
patient
seen
frequent
exposur
prescript
pep
clinician
attun
advers
event
potenti
psycholog
stress
lassa
viru
exposur
rel
contraind
ribavirin
pep
includ
sever
anemia
hemoglobinopathi
pregnanc
breastfeed
coronari
arteri
diseas
renal
insuffici
decompens
liver
diseas
known
hypersensit
case
clinician
discuss
risk
benefit
patient
baselin
hemoglobin
hematocrit
level
measur
therapi
reconsid
signific
anemia
present
complet
blood
count
bilirubin
level
recheck
day
initi
drug
ribavirin
stop
dose
adjust
signific
anemia
note
physician
awar
long
termin
halflif
h
larg
volum
distribut
ribavirin
mean
drug
may
still
effect
time
even
cessat
particularli
red
blood
cell
accumul
propos
specif
guidelin
use
ribavirin
pep
lassa
fever
hope
use
clinician
manag
often
difficult
unfamiliar
situat
guidelin
may
also
serv
pep
arenavirus
caus
hemorrhag
fever
junin
machupo
guanarito
flexal
virus
well
crimeancongo
hemorrhag
fever
viru
although
efficaci
trial
involv
human
like
imposs
studi
nonhuman
primat
conduct
confirm
efficaci
oral
ribavirin
pep
diseas
data
could
also
guid
decis
whether
oral
ribavirin
merit
inclus
us
strateg
nation
stockpil
vitro
vivo
test
conduct
assess
efficaci
newer
antivir
arenavirus
hemorrhag
fever
virus
consider
pep
treatment
regimen
could
includ
drug
alreadi
licens
indic
well
promis
drug
still
experiment
stage
